Macrophage efferocytosis pathway

The **macrophage efferocytosis pathway** is not a single molecule or canonical drug target but rather describes the orchestrated, multi-step biological process by which professional phagocytes—primarily macrophages—recognize, engulf, and degrade apoptotic (dying) cells. This process prevents secondary necrosis, resolves inflammation, and maintains tissue homeostasis. Recognition begins with “find me” signals (e.g., CX3CL1, S1P, lysophosphatidylcholine) from apoptotic cells, drawing macrophages to sites of cell death. Macrophage surface receptors—such as the TAM receptor tyrosine kinases (MerTK, AXL, Tyro3), T cell immunoglobulin and mucin receptors (TIMs), scavenger receptor class B type I, LRP1/CD91, and BAI1—bind “eat me” signals (notably phosphatidylserine) on apoptotic cell surfaces, either directly or through bridging molecules (e.g., Gas6, Protein S, MFG-E8). Signaling cascades subsequently activate small GTPases like Rac1, which remodel the cytoskeleton for phagocytosis. After engulfment, phagosome-lysosome fusion enables digestion of cell remnants, and subsequent metabolic reprogramming of the macrophage—involving the pentose phosphate pathway and glycolysis—favors anti-inflammatory, pro-resolving states. Defective efferocytosis is implicated in atherogenesis, chronic inflammation, autoimmune disorders, cancer, and neurodegeneration. While no therapies yet target this pathway as a whole, multiple experimental drugs and biologics modulate its key components, with active research focusing on enhancing efferocytosis to promote resolution in chronic inflammatory diseases and atherosclerosis, or—in some circumstances—dampening it to avoid tumor immune escape[1][2][3][4][5][6][7]. **Critical note:** This entry, "Macrophage efferocytosis pathway," is a **biological pathway** and not a specific molecular target (such as a receptor, enzyme, or transporter). It describes the coordinated function of many molecules, which are themselves drug targets. Therefore, _is_target: false_ and _is_incorrect: true_ for the context of structured drug target annotation. For drug discovery or translational research, you would usually specify an individual efferocytosis receptor (e.g., "MerTK receptor," "AXL receptor," "TIM-4 receptor") rather than the entire pathway.

Other names

Efferocytosis pathwayMacrophage-mediated efferocytosisApoptotic cell clearance by macrophages

Drugs modulating this pathway typically act by enhancing or inhibiting macrophage phagocytic receptors (e.g., TAM, TIM, LRP1) or altering downstream cytoskeletal and metabolic signaling (e.g., PI3K/Akt, Rac1, noncanonical pentose phosphate pathway)[1][2][5][7]. Other agents alter “find me”/“eat me” signal recognition (e.g., boosting Gas6, Protein S, S1P signaling)[1][2][5].